Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;8(3):513-523.
doi: 10.21037/jgo.2016.04.03.

Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma

Simon B Zeichner  1 , Daniel A Goldstein  2 , Christine Kohn  3 , Christopher R Flowers  1
Affiliations
Review

Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma

Simon B Zeichner et al. J Gastrointest Oncol. 2017 Jun.

Abstract

Over the past 20 years, with the incorporation of genetic sequencing and improved understanding regarding the mechanisms of cancer growth/metastasis, novel targets and their associated treatments have emerged in oncology and are now regularly incorporated into the clinical care of patients in the US. Novel, more tumor-specific, non-chemotherapy agents, including agents that are commonly used in the treatment of patients with gastric adenocarcinoma (GA) and gastrointestinal stromal tumor (GIST), fall under a broader treatment strategy, termed "precision medicine". While diagnostic testing and associated treatments in metastatic GA (mGA) are costly and may produce marginal benefit, those associated with GIST, despite being costly, produce significant improvements in patient outcomes. Despite the significant difference in impact, the agents associated with these cancers have similar acquisition costs. In this paper, we will review the current literature regarding cost and cost-effectiveness associated with precision medicine diagnosis and treatment strategies for GA and GIST.

Keywords: Cost-effectiveness; cost; gastric adenocarcinoma (GA); gastrointestinal stromal tumor (GIST); targeted agents.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 10.3322/caac.21332 - DOI - PubMed
    1. SEER Stat Fact Sheets: Stomach Cancer. Available online: http://seer.cancer.gov/statfacts/html/stomach.html. Accessed January 5th, 2016.
    1. Call J, Walentas CD, Eickhoff JC, et al. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer 2012;12:90. 10.1186/1471-2407-12-90 - DOI - PMC - PubMed
    1. Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 2012;43:413-22. 10.1016/j.humpath.2011.05.019 - DOI - PubMed
    1. President Obama Announces Plans for New Precision Medicine Initiative. American Association for Cancer Research. Available online: http://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Pages/CPM150210-pre...